Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cholesterol ester synthase ACAT1 inhibitor in preparation of medicine for preventing/treating non-alcoholic fatty liver disease

A non-alcoholic, cholesteryl ester technology, applied in the field of medicine, can solve the problems of no unified conclusion on the pathogenesis, no cholesteryl ester prevention and treatment of non-alcoholic fatty liver research reports, etc.

Pending Publication Date: 2021-03-16
JIANGNAN UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of NAFLD is still inconclusive, and there are no relevant research reports on the impact of cholesteryl esters on non-alcoholic fatty liver and the use of cholesteryl ester inhibitors to prevent and treat non-alcoholic fatty liver

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cholesterol ester synthase ACAT1 inhibitor in preparation of medicine for preventing/treating non-alcoholic fatty liver disease
  • Application of cholesterol ester synthase ACAT1 inhibitor in preparation of medicine for preventing/treating non-alcoholic fatty liver disease
  • Application of cholesterol ester synthase ACAT1 inhibitor in preparation of medicine for preventing/treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Medication method: Select 30 adult SPF grade C57BL / 6 male mice with high sensitivity to establish non-alcoholic fatty liver model, and divide them into 3 groups, 10 in each group. After one week of adaptive feeding, one group of 10 mice was used as a negative control group, fed with 30% fatty acid and 2% cholesterol combined feed; the other two groups were fed with 30% fatty acid and 2% cholesterol combined feed, and were orally gavaged at the same time Administer 250 mg / kg / day of avasimibe (ACAT inhibitor) and esetrapib (CETP inhibitor) for 12 consecutive weeks; mice in the negative control group were given normal saline. Animals were processed after 12 weeks of continuous feeding, and blood and liver tissues were collected.

[0020] The content of triglyceride (TG) in the liver of animals in each group was measured, and the fatty degeneration of liver tissue was observed by HE and oil red staining.

[0021] In order to observe the effect of avasimibe on the steatosis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a cholesterol ester synthase ACAT1 inhibitor in preparation of a medicine for preventing / treating non-alcoholic fatty liver disease, and belongs to the fieldof biomedicines. According to the invention, the cholesterol ester synthetase ACAT1 inhibitor-avasimibe is used for preventing / treating the non-alcoholic fatty liver disease, and in-vivo animal experiment results show that the avasimibe can reduce fat deposition in the liver of a high-fat animal model mouse and improve the fatty degeneration degree of the liver, so that the avasimibe has the effect of improving the non-alcoholic fatty liver disease. The avasimibe as the medicine and a medicine composition has a good application prospect in the aspect of preventing and treating the non-alcoholic fatty liver disease, and the development potential is very great.

Description

technical field [0001] The invention specifically relates to the application of a cholesteryl ester synthase ACAT1 inhibitor in the preparation of a drug for preventing / treating non-alcoholic fatty liver, and belongs to the field of medicine. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty degeneration and fat accumulation in hepatic parenchymal cells without a history of excessive alcohol consumption. Non-alcoholic fatty liver disease is the first cause of chronic liver disease in developed countries such as the West and Japan, and ranks second only to viral hepatitis in my country. In recent years, due to the improvement of people's living standards, unreasonable diet structure and improper preventive and health care measures, the incidence of fatty liver is increasing year by year, and the age of onset is getting younger and younger. In developed countries, the incidence rate is 20%-30%. . ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/185A61K45/06A61P1/16A61P35/00
CPCA61K31/185A61K45/06A61P1/16A61P35/00
Inventor 陈永泉韦冷云朱升龙王小英
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com